High concordance of BAP1 and PBRM1 expression in patient-matched primary and metastatic ccRCC tumors.

Authors

null

Amanda Shreders

Mayo Clinic, Jacksonville, FL, Jacksonville, FL

Amanda Shreders , Richard Wayne Joseph , Daniel Serie , Payal Kapur , Thai Huu Ho , Jeanette Eckel-Passow , James Brugarolas , Alexander S. Parker

Organizations

Mayo Clinic, Jacksonville, FL, Jacksonville, FL, The University of Texas Southwestern Medical Center, Dallas, TX, Mayo Clinic, Scottsdale, AZ, Scottsdale, AZ, Mayo Clinic, Rochester, MN, Rochester, MN

Research Funding

No funding sources reported

Background: Clear cell renal cell carcinoma (ccRCC) is a well-described molecularly heterogeneous tumor. Herein, we assessed the concordance of two of the most commonly mutated genes in ccRCC, PBRM1 (~50%), and BAP1 (~15%), in patient-matched primary and metastatic tumors. Methods: One pathologist (PK) assessed PBRM1 and BAP1 protein expression using immunohistochemistry (IHC) in 99 patients with a primary and at least one metastatic ccRCC tumor available for analysis. All available metastatic tumors were analyzed. Results: A total of 99 patients (48 M0 and 51 M1) had both a primary tumor and at least one metastatic tumor available for analysis. There were a total of 158 metastases with one patient having up to 7 metastases available for analysis. The concordance between primary and patient-matched metastasis was 87% for PBRM1 and 99% for BAP1. We observed a similar concordance between patients with M0 versus M1 disease. Conclusions: While ccRCC is molecularly heterogeneous, PRBM1, and BAP1 are largely concordant between primary and metastatic lesions suggesting that PBRM1 and BAP1 are genetically truncal events in the molecular pathogenesis of ccRCC.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 507)

DOI

10.1200/jco.2015.33.7_suppl.507

Abstract #

507

Poster Bd #

H19

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Genitourinary Cancers Symposium

The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma.

First Author: Zilin Wang

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.

First Author: Gentry Teng King

Abstract

2024 ASCO Genitourinary Cancers Symposium

High expression of sialylated cancer-derived IgG and survival in metastatic clear cell renal cell carcinoma.

First Author: Jie Wu